NCT00416494View on ClinicalTrials.gov

Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

August 31, 2014

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

bevacizumab

10 mg/kg intravenously over 30-90 minutes on day 1

DRUG

oxaliplatin

85 mg/m2 intravenously over 2 hours on day 1.

DRUG

Capecitabine

Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort

DRUG

Capecitabine

Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Herbert Hurwitz, MD

OTHER

NCT00416494 - Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer | Biotech Hunter | Biotech Hunter